Related references
Note: Only part of the references are listed.Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience
Ann Brinch Madelung et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells
Yuxia Zhang et al.
BLOOD (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
Bridget S. Wilkins et al.
HAEMATOLOGICA (2013)
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia
T. Barbui et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
Richard T. Silver et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
Umberto Gianelli et al.
MODERN PATHOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
Giovanni Barosi et al.
PLOS ONE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MPN-associated myelofibrosis (MPN-MF)
R. A. Mesa et al.
LEUKEMIA RESEARCH (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: A computer-assisted image study
Carolin J. Teman et al.
LEUKEMIA RESEARCH (2010)
Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
Peter J. Campbell et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis
Claudia Vener et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
Bridget S. Wilkins et al.
BLOOD (2008)
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Myelofibrosis - What's in a name? Consensus on definition and EUMNET grading
Juergen Thiele et al.
PATHOBIOLOGY (2007)
Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading
George E. Sale et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera
Hans Michael Kvasnicka et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis
J Thiele et al.
ANNALS OF HEMATOLOGY (2006)
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients
J Thiele et al.
HISTOPATHOLOGY (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis
J Thiele et al.
HISTOPATHOLOGY (2003)
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens
T Buhr et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: A follow-up study on 309 patients
J Thiele et al.
LEUKEMIA & LYMPHOMA (2003)
Primary autoimmune myelofibrosis: Definition of a distinct clinicopathologic syndrome
V Pullarkat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients
J Thiele et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
